Event context for CONMED and recent performance snapshot

Recent commentary on CONMED (CNMD) highlights adoption of its AirSeal, Buffalo Filter, and BioBrace platforms alongside tariff and product specific growth risks. Investors are weighing this product mix against the stock’s recent share price moves.

See our latest analysis for CONMED.

At a share price of US$49.26, CONMED has seen its 30 day share price return of 14.03% and 90 day share price return of 33.10% contrast with a 1 year total shareholder return that declined 9.27%. This signals recent momentum against a weaker multi year record that investors are reassessing in light of adoption trends for AirSeal, Buffalo Filter, and BioBrace.

If you want to broaden your watchlist beyond CONMED and look for other ideas in healthcare related technology, a good next step is to review the 42 healthcare AI stocks

After a sharp rebound yet a weaker multi year track record, some investors may see CONMED’s current price as a second chance, while others prefer to wait for a pullback. How does the valuation stack up against that trade off now?

Most Popular Narrative: 8.3% Overvalued

CONMED’s most followed narrative pegs fair value at $45.50, which sits below the last close of $49.26 and frames the recent rebound as slightly ahead of that view.

The analysts have a consensus price target of $45.5 for CONMED based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $179.7 million, and it would be trading on a PE ratio of 8.8x, assuming you use a discount rate of 8.5%.

Read the complete narrative.

Want to see what underpins that fair value for CONMED? The narrative leans on a specific blend of revenue growth, margin expansion, and a lower future earnings multiple.

On these assumptions, the narrative suggests that CONMED’s current share price is modestly ahead of the implied fair value, rather than deeply disconnected from it. The discount rate used is 8.51%, which shapes how analysts translate those future revenue and earnings paths into today’s dollars and influences how sensitive that $45.50 figure is to any change in expectations.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CONMED still faces supply chain recovery questions and ongoing reliance on hospital capital spending, which could pressure growth expectations and challenge that fair value narrative.

Find out about the key risks to this CONMED narrative.

Another View on CONMED’s valuation

Analysts see CONMED as 8.3% overvalued relative to their US$45.50 fair value estimate, yet our DCF model points the other way. On SWS numbers, the stock trades around US$49.26 compared with an estimated future cash flow value of US$107.20, which implies a wide upside gap. Which lens do you think better fits the risks around debt, margins, and execution quality?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With sentiment split on CONMED’s upside and risks, it makes sense to review the numbers now and decide where you stand. For a concise snapshot of both sides of the story, start with the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond CONMED?

If you are serious about sharpening your portfolio, do not stop with CONMED. Use focused stock lists to spot opportunities before they move out of reach.

• Target future upside potential by reviewing companies on the screener containing 20 high quality undiscovered gems that already show strong underlying fundamentals.
• Strengthen your defensive side with the 79 resilient stocks with low risk scores that highlights businesses scoring well on resilience and risk control.
• Anchor your portfolio with quality by using the solid balance sheet and fundamentals stocks screener (50 results) to focus on companies backed by sturdier finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.